Showing 841-850 of 9143 results for "".
Cellfina Cleared, Finacea Foam Approved
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-cellfina-cleared-finacea-foam-approved/18866/The FDA has cleared Cellfina (Ulthera Inc./Merz Aesthetics, Inc.) to treat cellulite, with results lasting for up to 2 years. Finacea Foam (azelaic acid, Bayer Dermatology) is approved for Rosacea, and Almirall invests in Suneva Medical, maker of Bellafill. Also in this edition, a look at the data oPreserve the Core; Live Your Aesthetic
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/preserve-the-core-live-your-aesthetic/19083/Heidi Waldorf, MD, FAAD and Steven Dayan, MD, FACS, Co-Chief Medical Editors of Modern Aesthetics®magazine, talk about the importance of staying true to your aesthetic and address the challenges of preserving the core specialties.Sunscreen Water Seems All Washed Up; Fake Cosmeceuticals Raise Concerns
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-sunscreen-water-seems-all-washed-up-fake-cosmeceuticals-raise-concerns/19119/In this edition of DermWireTV, from the publishers of Practical Dermatology® magazine we take a look at drinkable sunscreen and school bans on sunscreens, get an update on Vegas Cosmetic Surgery, and meet the new face of AMBI skincare. Plus, our DermFocus investigates the problem of counterfeit cosHoya ConBio - The Medlite Peel
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/hoya-conbio-the-medlite-peel/19455/A specific patient case is demonstrated to show the outcome of using the Medlite as a laser peel. Valuable tips and suggestions are given by Dr. Brian Rubach.New Clinical Guidelines for Nonmelanoma Skin Cancer Treatment; Arctics Biotherapeutics Seeks New FDA Approval for ZORYVE Foam
https://practicaldermatology.com/series/dermwire-tv/new-clinical-guidelines-for-nonmelanoma-skin-cancer-treatment-arctics-biotherapeutics-seeks-new-fda-approval-for-zoryve-foam/26745/In this week’s DermwireTV, new clinical guidelines for nonmelanoma skin cancer treatment; Arcutis Biotherapeutics seeks new FDA approval for ZORYVE foam; Practical Dermatology joins the ReachMD network; and the CEO of SofWave Medical joins us to discuss the company’s Ultrasound technology.Study Examines Association Between Childhood BMI and Risk of Developing IMSDs
https://practicaldermatology.com/series/dermwire-tv/study-examines-association-between-childhood-bmi-and-risk-of-developing-imsds/27004/In this week's DermwireTV, a new study examines the relationship between childhood BMI and skin diseases; phase 3 data sheds new light on dupilumab’s effect on inflammatory biomarkers in pediatric AD patients; and the president and CEO of Evolus discusses trends in the injectables market.Calling Out Hesitation on Systemics
https://practicaldermatology.com/programs/practical-dermatology/calling-out-hesitation-on-systemics/35703/The latest news and updates, plus Jason E. Hawkes, MD, MS, FAAD, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss why dermatologists should not be reluctant to prescribe systemic therapies, and Linda F. Stein Gold, MD, discusses the importance of an ever-expanding aThe Impact of Clascoterone Topical Cream, 1%: The US Experience 4 Years After Approval and Clinical Expectations for Acne Patients in Other Regions of the World
https://practicaldermatology.com/topics/acne-rosacea/Impact-Clascoterone-Topical-Cream/32830/Clascoterone topical cream, 1% (Winlevi), approved by the US Food and Drug Administration (FDA) in 2020 as the first novel drug introduced for the treatment of acne vulgaris since 1982, is indicated in the US for patients 12 years of age and older. The safety and efficacy were supported by two succeVtama Approved for AD in Adults and Children
https://practicaldermatology.com/series/dermwire-tv/vtama-approved-ad-adults-and-children/30079/In this week's DermwireTV, the FDA approves Vtama (tapinarof cream 0.1%) for atopic dermatitis in adults and children; the FDA approves Nemluvio (nemolizumab) for moderate-to-severe AD; and the president of Nuance Medical discusses the acquisition of scar treatment brand, Biocorneum.Dr. Battle on Skin of Color Update and Minimizing, Treating Complications from Energy-Based Devices
https://practicaldermatology.com/topics/skin-of-color/dr-battle-skin-color-update-and-minimizing-treating-complications-energy-based-devices/28655/Eliot Battle, MD, discusses the growth of Skin of Color Update, minimizing and treating complications when treating patients of skin of color, and integrating energy-based devices into your practice.